Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proderm
- Development stage
- Unknown
- Lead developer
- Ferndale Laboratories
- Administration
- Topical
01
Overview
Proderm (marketed as Pro-Q in the United States) is a topical barrier repair emollient formulated as a foam or mousse, specifically designed to address skin barrier impairment in patients with atopic dermatitis. It functions by enhancing the hydration of the stratum corneum and reducing transepidermal water loss (TEWL). Clinical evaluations using electrical impedance and other non-invasive biophysical methods have demonstrated that Proderm can normalize skin hydration and structural integrity in atopic individuals. The product is typically used as a non-steroidal maintenance therapy to manage xerosis and prevent inflammatory flares by restoring the skin's natural protective function.
- Brand names
- ProdermPro-Q
Beyond the preview
Go deeper on Proderm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proderm.